Laurel Wealth Planning’s Bristol-Myers Squibb BMY Stock Holding History

Laurel Wealth Planning’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,025	Closed	-$73.7K	–	82
2022 Q4	$73.7K	Hold	1,025	–	–	0.05%	93
2022 Q3	$73K	Hold	1,025	–	–	0.05%	87
2022 Q2	$79K	Sell	1,025 -725	-41%	-$55.2K	0.06%	87
2022 Q1	$128K	Buy	+1,750	New	+$118K	0.09%	80

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Laurel Wealth Planning's BMY Position: Q1 2023 in Review

Laurel Wealth Planning sold out of Bristol-Myers Squibb (BMY) in Q1 2023, closing a stake of 1,025 shares — an estimated $73.7K sold.

Laurel Wealth Planning first reported a position in BMY in Q1 2022 and held it in 4 quarters. The position peaked at $128K in Q1 2022. 2,540 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

Laurel Wealth Planning reported no remaining Bristol-Myers Squibb position as of Q1 2023 after selling out during the quarter.
Laurel Wealth Planning sold 1,025 Bristol-Myers Squibb shares in Q1 2023, an estimated $73.7K.
Laurel Wealth Planning first reported a position in Bristol-Myers Squibb in Q1 2022 and held it in 4 quarters.
Laurel Wealth Planning's Bristol-Myers Squibb position peaked at $128K in Q1 2022.
2,540 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on Laurel Wealth Planning's 13F filing for Q1 2023, filed 18 Apr 2023.